|
https://www.fiercepharma.com/financials/cosentyx-woes-generi… The No. 1 concern among analysts during the first-quarter earnings call was psoriasis drug Cosentyx, which brought in $580 million, significantly short of the average estimate of $635 million. The company blamed destocking by specialty pharmacies and rebates it offered to win more prescriptions in previously untreated patients. But there’s no doubt Novartis faces increasing pressure from both rivals and payers in this market. It had an early, first-to-the-punch lead in 2015 but has since acquired tough rivals in Johnson & Johnson’s Tremfya, Eli Lilly’s Taltz and Valeant’s Siliq. |
|
| aus der Diskussion: | Bausch Health ehemals VALEANT PHARMA Allergan-Übernahme beflügelt |
| Autor (Datum des Eintrages): | marty44 (02.05.19 10:45:25) |
| Beitrag: | 3,726 von 4,274 (ID:60469661) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |